ストックスクリーナーアプリを入手
14.41
0.35%
-0.05
アフターアワーズ：
14.41
前日終値:
$14.46
開ける：
$14
24時間の取引高:
1.75M
Relative Volume:
0.72
時価総額：
$1.67B
収益：
-
当期純損益:
$-294.51M
株価収益率:
-4.0478
EPS:
-3.56
ネットキャッシュフロー:
$-244.42M
1週間 パフォーマンス:
-1.97%
1か月 パフォーマンス:
+19.09%
6か月 パフォーマンス:
-44.00%
1年 パフォーマンス:
-57.23%
1日の値動き範囲:
$13.80
$14.64
1週間の範囲:
$13.80
$15.23
52週間の値動き範囲:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
DYN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
14.41 | 1.67B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: FDA - openPR.com
Dyne Therapeutics (DYN) Receives "Outperform" Rating by Raymond James | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN): Analyst Sets Positive Outlook with $37 Price Target | DYN Stock News - GuruFocus
Dyne Therapeutics officer sells shares worth $1,949 By Investing.com - Investing.com Canada
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com
Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DYNE-302 for FSHD | DYN Stock News - GuruFocus
Dyne Therapeutics to Present New Preclinical Data in Facioscapul - GuruFocus
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress - The Manila Times
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress | DYN Stock News - GuruFocus
Dyne Therapeutics Announces Functional Improvement of DYNE-302 in FSHD Preclinical Model - Nasdaq
Breakthrough: New FSHD Treatment Restores Muscle Function in Single Dose, Dyne Reports - Stock Titan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 56.1% in May - Defense World
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Oppenheimer - Defense World
Dyne Therapeutics (DYN) Target Price Adjusted by Oppenheimer | D - GuruFocus
Oppenheimer Sees Potential in Dyne Therapeutics (DYN) with Revis - GuruFocus
Oppenheimer Adjusts Dyne Therapeutics Price Target to $34 From $60, Maintains Outperform Rating - marketscreener.com
(DYN) Technical Data - news.stocktradersdaily.com
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5.5% – Here’s What Happened - Defense World
Bank of America Corp DE Decreases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Evercore ISI - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne Therapeutics (DYN) Receives Outperform Rating as Confidence Grows | DYN Stock News - GuruFocus
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
Ameriprise Financial Inc. Increases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Inc (DYN) Volatility Hits 6.09%: What Good Investors Need To Be Aware Of - Stocksregister
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets - Defense World
Antibody Conjugate Oligonucleotide Market Research 2025-2035, Competitive Analysis of Key PlayersAvidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and AstraZenecaResearchAndMarkets.com - Bluefield Daily Telegraph
Dimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Northern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
H.C. Wainwright cuts Dyne Therapeutics target to $38 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Dyne Therapeutics target to $38 - Investing.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics (DYN) Price Target Lowered by HC Wainwright & Co. | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN - GuruFocus
RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsDYN - ACCESS Newswire
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Eyes Accelerated Approval for Key Programs by 2026 | DYN Stock News - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):